Open Access

ARTICLE

A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab

Tsung-Kun Chang^*†, Tzu-Chieh Yin^‡§, Wei-Chih Su^*†, Hsiang-Lin Tsai^*¶, Ching-Wen Huang^*¶, Yen-Cheng Chen^*, Ching-Chun Li^*, Po-Jung Chen^*, Cheng-Jen Ma^*§, Kuo-Hsiang Chuang^#, Tian-Lu Cheng^**, Jaw-Yuan Wang^{*†¶††‡‡§§}

* Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
† Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
‡ Department of Surgery, Kaohsiung Municipal Tatung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
§ Division of General and Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
¶ Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
# Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan
** Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, Taiwan
†† Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
‡‡ Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan
§§ Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan